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ABSTRACT 
 
Bisphosphonates are a class of drugs used to strengthen bone. They are indicated in the treatment of osteoporosis 
and Paget's disease as well as malignant pathologies such as breast cancer, bone metastases. The examples  of 
medications bisphosphonates includes Aledronate, Ibandronate, Incadronate, Olpadronate, Pamidronate, 
Risedronate, and Zoledronate. One of the most important complications of bisphosphonates is osteonecrosis of the 
jaws which alters the quality of life of the patient and is all the more difficult to manage as osteonecrosis is 
advanced. This paper describes two cases of advanced osteonecrosis whose management was very difficult leading 
to a recurrence of this complication. 
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Introduction 
 
 
Osteonecrosis of the jaws associated 
with bisphosphonate therapy, has been identified and 
defined as a pathological entity since 2003 [8]. The 
definitive symptom of Osteonecrosis of the jaws is the 
exposure of mandibular or maxillary bone through 
lesions in the gingiva that do not heal. Pain, 
inflammation of the surrounding soft tissue, secondary 
infection or drainage may or may not be present [10] 
.The development of lesions is most frequent after 
invasive dental procedures, such as extractions, and is 
also known to occur spontaneously. There may be no 
symptoms for weeks or months, until lesions with 
exposed bone appear [10].The recommended treatment 
for this osteonecrosis is essentially symptomatic and 
conservative [6, 10]. However, in advanced cases, the 
treatment seems more complicated and the resolution 
of the problem is inconclusive. 
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Clinical Observation 
 
Case report n°1 
 
Mister A.L, 62-year-old, consulted in the service 
(department) in September 2007 for pains and delay of 
gingival healing after maxillo-mandibular multiple 
dental extractions realized on 1 year previously. On 
general examination, the patient showed that it had a 
multiple myeloma with IgG of IIIa stage, treated since 
May 2000 by radiotherapy, chemotherapy (Melphlan), 
Dexamethasone, 5 monthly cures of Pamidronate then 
13 monthly cures of Acid Zoledronic. In September 
2006, 46, 47 and 48 were extracted because of a 
mandibular pain on posterior right side which was 
followed by a mandibular tumefaction, painful and 
infected, at the site of extractions and not yielding to 
the antiseptic and antibiotic treatment. Extraorally, 
there was a cutaneous fistula facing the osteitis focus 
which drained a purulent exudate associated with a 
hard swelling and painful in the right side with a 
homolateral labio-chin hypoesthesia (fig 1).Intraoral 
examination revealed the absence of 18, 17, 16, 15, 24, 
25, 27, 28, 44, 45, 46, 47 and 48 and two mucous 
ulcerations with osseous exposure interesting the 
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jawbone and the mandible in the right posterior area 
(fig 2). 
The radiological assessment (panoramic x-ray and CT 
of the facial mass) showed a loss of osseous substance 
with pathological mandibular fracture (fig 3), which 
justified the realization of surgical debridement under 
general anesthesia associated with reconstruction by an 
osteosynthesis plate.  
             The histopathological examination revealed an 
osteitis colonized by Actinomyces without signs of 
malignity. An antiseptic treatment and antibiotic by 
amoxicilline were prescribed during 50 days. After 4 
months, the panoramic radiography showed the 
persistence of the mandibular osteitis. 
 
Consequently, in May 2007, a second surgical 
debridement with removal of the mini-plate of 
osteosynthesis was made. 
The microscopic examination specified that it was an 
osteonecrosis without histological sign of malignity. 
An antiseptic treatment, an antibiotic 
(quinolone/métronidazole) and a hyperbaric oxygen 
therapy (20 sessions) were made. 
Radiological control, one month after, showed a loss of 
osseous substance extended in the right   posterior 
mandibular area and a good bone healing in the 
maxillary. The patient died in December 2007 of a 
severe pulmonary attack, secondary to his myeloma. 
Case report n°2 
 
A 45-year-old female presented to the Department of 
Oral surgery for pains and a left swelling in her cheek. 
On general examination, the patient reports that she has 
a breast cancer treated with intravenous 
bisphosphonates Zoledronate “ZOMETA” for three 
years. The patient added that she developed a femoral 
metastasis. Three months ago she performed an 
extrusion of a premolar which was followed by a 
swelling at the site of extraction, pain and lack of 
healing. An antibiotic by amoxicilline and 
metronidazole treatment was introduced without 
success. The situation continued for a three month 
period before referral to our department. Extraorally 
there was a facial asymmetry due to a swelling with 
tender left submandibular lymphadenopathy (fig 4). 
Intra-orally, the presence of a non-healing extraction 
site 35 with inflamed gingival tissue and necrotic bone 
was noted (fig 5).   
The radiological assessment (Panoramic x ray and CT 
of the facial mass) discovered an osteolysis extended in 
the left posterior area of the horizontal branch.  
A surgical debridement consisted of a curettage of soft 
bone in the premolar region was performed and soft 
tissue closure again attempted. A long-term antibiotic 
regime was prescribed (Amoxicilline during one 
month). 
A histological report demonstrates necrotic bone. The 
surgery allowed to temporarily control the symptoms, a 
recurrence was noted after a few weeks. The choice of 
a conservative surgery was decided following the 
patient's deteriorated health. The patient died of the 
complications of her initial illness. 
 
Discussion 
Bisphosphonates are structural analogues of inorganic 
pyrophosphates, having a big affinity for the bone by 
being bound strongly in the hydroxyapatite [1].  
Bisphosphonates are indicated in skeletal disorders, 
such as bone metastases, myeloma, osteoporosis, paget 
disease, and bone pain.  
Those that contain nitrogen (N-BPs) are the most 
potent ones and are represented by Aledronate, 
Ibandronate, Incadronate, Olpadronate, Pamidronate, 
Risedronate, and Zoledronate. Whereas the non–N-BPs 
are mainly Clodronate, Etidronate, and Tiludronate [2]. 
 
Maxillary osteonecrosis due to bisphosphonates is 
defined by the presence of exposed bone in the 
maxillofacial region which persists for at least eight 
weeks in patients on bisphosphonates with no history 
of local radiotherapy or maxillary metastases [3].  
This complication is found, most commonly, in 
patients with Multiple myeloma, aged 61 years 
Average, white race. It sits with predilection in the 
posterior mandibular region [4, 1]  
The physiopathogenesis of osteonecrosis of the jaws is 
not clearly understood [3]. The most accepted theory is 
that exposed bone is the result of a disruption of the 
osteoblast-osteoclast homeostatic cycle due to 
Bisphosphonates [1,2] .This has the effect of disturbing 
the osteoclastic functions, which interrupts the normal 
turn-up, inducing an old bone that is not eliminated 
with excessive mineralization of the bone weave [5].  
Several risk factors such as treatments using 
Pamidronate or Zoledronic acide , tooth extraction, the 
patient's advanced age at the time of diagnosis , the 
dose and duration of exposure to bisphosphonates 
greater than 2.5 years increase the risk of developing 
osteonecrosis of the jaws [4,5,6,7]. 
Other treatments, namely chemotherapy and 
corticosteroids, could also play a role in the 
development of these osteonecrosis [7]. 
The clinical signs of osteonecrosis of the maxilla 
depend on the stage of the disease. Osteonecrosis of the 
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maxilla can be asymptomatic or present as an 
unexplained discomfort with frustrated objective signs 
affecting the quality of life of the patient [8]. 
These clinical signs can be more important ranging 
from the mobility of teeth, pain or neurosensory 
changes (paraesthesia) to infectious signs (cellulitis, 
extra-oral fistula) [8]. 
Routine radiographic evaluation for hard tissue 
radiolucencies may indicate the onset of early stage 
osteonecrosis of the jaws. Radiopaque changes 
associated with the lamina dura may also indicate 
continued osteoblastic activity without osteoclastic 
resorption [9]. This radiological aspect is non-specific 
and should be differentiated from chronic 
osteomyelitis, infected osteoradionecrosis, primary 
bone tumor pathology (myeloma), metastasis and a 
pathological fracture of the maxilla [3]. 
Histopathological examination shows bone necrosis 
associated with bacterial infection and granulation 
tissue. The diagnosis of actinomycosis must be 
correlated with the results of the bacterial culture. In 
some cases, if a tumor bone metastasis is suspected, a 
bone biopsy should be performed [3]. Currently, the 
treatment recommended for osteonecrosis is essentially 
symptomatic and conservative. It consists of making 
antiseptic oral rinses (aqueous chlorhexidine 0.1%), 
antibiotic therapy in case of local infection, abscess or 
fistulization and surgical debridement treatment of the 
necrotic bone with elimination of mobile osseous 
sequesters [2, 3, 8].In some cases of extensive 
osteonecrosis, only aggressive treatment (interrupted 
resection of the mandible) makes it possible to obtain 
the resolution of the pain and the acute infection [3]. 
According to Ruggiero and Marx [3,10] a segmental 
resection associated with immediate reconstruction by 
an osteosynthesis plate is necessary during a 
pathological mandibular fracture. 
On the other hand, mandibular reconstruction 
immediately with a bone graft vascularized or not 
cannot be considered because there is a risk of bone 
necrosis on the site because of the systemic effect of 
bisphosphonates [3].Hyperbaric oxygen administration 
seems to be helpful in this direction, especially for 
major mandibular defects, but it is needed to be 
clarified by with sufficient data [2].The discontinuity 
of bisphosphonate therapy does not seem to be justified 
because of their long bone half-life [3]. However, 
Magopoulos et al [2], suggested that the cessation of 
bisphosphonate therapy for more than 6 months 
followed by debridement/sequestration of the defect 
with concomitant antibiotics administration resulted in 
complete wound healing in several cases [2].Elective 
dento-alveolar surgical procedures such as extractions, 
dental implants or endodontic surgery, should be 
avoided because they may promote the development of 
osteonecrosis [3]. 
 
Conclusion 
 
The management of these patients with bisphosphonate 
induced osteonecrosis of the jaws is quite challenging 
[2].The major goal of treatment for patients who have 
osteonecrosis of the jaws is preservation of quality of 
life through: patient education and reassurance, control 
of pain, control of secondary infection and prevention 
of extension of lesion and development of new areas of 
necrosis [8].However, in advanced cases, management 
of this complication is difficult and the recidivism is 
inevitable [8]. 
 
                   
Fig 1:  Cutaneous fistula in the right 
 submandibular region 
Fig 2 : Necrosis and bone infection  
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Fig 3 : Pre-operative X- Ray (3a: Dental panoramic, 3b: CT axial) 
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